Lilly, Boehringer tweak diabetes alliance terms; Judges scrutinize Ackman's Allergan share before vote;

@FiercePharma: Top-read in FiercePharmaManufacturing Tues: Production issues for $GSK, Sanofi delay flu vaccines in the U.S. Article | Follow @FiercePharma

@EricPFierce: Ranbaxy's Ohm Laboratories plant comes to the rescue in last quarter, turning bottom line from red to black. FiercePharmaManufacturing story | Follow @EricPFierce

@CarlyHFierce: ICYMI yesterday: Pharma's top 10 M&A deals of H1 2014. Feature | Follow @CarlyHFierce

> Eli Lilly ($LLY) and Boehringer Ingelheim have revised the terms of their diabetes drugs alliance in some countries. Report

> A judge is examining Bill Ackman's accumulation of $5.3 billion of Allergan ($AGN) stock to decide whether he can vote his 9.7% stake at Allergan's Dec.18 special shareholder meeting. More

> Indian drugmaker Dr. Reddy's missed the Street's latest quarterly estimates on muted U.S. growth and a sharp decline in Russia. Report

> A fund to pay for cancer drugs that are not available on the U.K.'s National Health Service "papers over" deeper drug pricing issues, a charity says. More

Medical Device News

@FierceMedDev: ICYMI yesterday: Welch Allyn partners with startup Gentag to create wearable devices. Article | Follow @FierceMedDev

@VarunSaxena2: UPDATED: Dx company Alere sells its health services unit for $600M amid continued restructuring. More | Follow @VarunSaxena2

@EmilyWFierce: Au revoir, Viehbacher. Reuters article | Follow @EmilyWFierce

> J&J Innovation's Ken Drazan on the future of med tech. Editor's Corner

> Medtronic announces first U.S. implant of investigational aortic heart valve. Article

Biotech News

@FierceBiotech: Armed with $48M bankroll, Aileron sets sights on p53 tumor target. Article | Follow @FierceBiotech

@JohnCFierce: $JNJ in China, deals getting struck on drug rights. Lots coming in Asia for biopharma. It's the new, new thing | Follow @JohnCFierce

@DamianFierce: "Categorical" second only to "fundamental" in corporate nonsensespeak--$AEGR. More from TheStreet | Follow @DamianFierce

@EmilyMFierce: Brain cells reprogrammed from skin cells offer treatment hope for Huntington's. FierceBiotech Research story | Follow @EmilyMFierce

> Cara's pain drug clears an abuse hurdle as it trots toward Phase III. News

> Xencor moves on without Amgen, ditching its hopes in arthritis. More

> Scripps cancer spinout Xcovery grabs $20M from a pharma partner in China. Article

Drug Delivery News

> Eye care company pSivida receives royalty payment, will spend it on pipeline. More

> BDSI aiming to develop injectable buprenorphine. Item

> Harvard team uses stem cells to deliver toxic doses to cancer cells. Report

> Microscale fibers may have many drug-delivery uses. Story

> Pfizer to withdraw from partnership to develop tamper-proof oxycodone formulation. Article

Diagnostics News

> InSilixa ropes in $13M from PointGuard Ventures and Morningside for molecular Dx tests. Story

> Johns Hopkins scientists develop real-time diagnostic system for drug-resistant bacteria. More

> FDA grants bioMérieux emergency authorization for one-hour Ebola Dx. Item

> 'See-through' sensors for the brain are transparent to imaging diagnostics. Story

> French scientists roll out rapid diagnostic test for Ebola. Article

Pharma Marketing News

> Love to hate Mr. Mucus? The Mucinex snot monster is back with a McCann makeover. Report

> For Novartis' respiratory ambitions, it's a tale of 'two worlds.' Story

> Sanofi board ousts CEO, aiming for a more 'cooperative' chief. Item

> Who's the diabetes price-cutting culprit: Lilly, Sanofi or Novo? More

> Orphan drug pricing for non-orphan meds? Express Scripts is looking at you, Gilead. Article

And Finally... In an insider trading probe, the SEC is innvestigating whether CMS employees leaked news on Dendreon's ($DNDN) Provenge. Report (sub. req.)

Suggested Articles

After Purdue’s record opioid settlement, more deals could be on the way. But that doesn’t mean all defendants are prepared to go quietly.

Now in their third quarter on the market, Gilead's own Epclusa and Harvoni generics have together grabbed more than 20% of the U.S. hep C market.

Purdue is seeking bankruptcy after inking a $10 billion-plus opioid settlement with thousands of cities and counties, plus two dozen states.